Fennec Pharmaceuticals INC Schedule 13G passive stakes

Rosalind Advisors Inc. and related entities have reported beneficial ownership of 9.6% of Fennec Pharmaceuticals Inc. common shares as of June 30, 2026.

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 7.2% of Fennec Pharmaceuticals Inc. common shares.

Rosalind Advisors Inc. and related entities have reported beneficial ownership of approximately 8.8% of Fennec Pharmaceuticals Inc. common shares as of March 31, 2026.

AIGH Capital Management and affiliated entities now beneficially own 5.7% of Fennec Pharmaceuticals' common shares, as disclosed in a Schedule 13G filing.

Sonic Fund II, L.P., along with Sonic GP LLC and Lawrence Kam, reported an aggregate beneficial ownership of 8.2% of Fennec Pharmaceuticals Inc.'s common stock as of December 31, 2025.

Rosalind Advisors, Rosalind Master Fund, and associated individuals have reported beneficial ownership exceeding 9% in Fennec Pharmaceuticals Inc.

Southpoint Master Fund and related entities have reported an 8.0% beneficial ownership stake in Fennec Pharmaceuticals Inc., holding 2,744,741 common shares.

Rosalind Advisors, Rosalind Master Fund, Steven Salamon, and Gilad Aharon have jointly disclosed a 7.46% beneficial ownership stake in Fennec Pharmaceuticals Inc.

Solas Capital Management, LLC and Frederick Tucker Golden have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 8.2% in Fennec Pharmaceuticals Inc. as of December 31, 2024.

DG Capital Management, LLC and affiliated entities have reported a reduction in their beneficial ownership of Fennec Pharmaceuticals Inc. common shares to 4.1%, falling below the 5% threshold.